Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

{"title":"PÓSTERES (PÓSTERES)","authors":"","doi":"10.1016/S2253-654X(25)00137-4","DOIUrl":"10.1016/S2253-654X(25)00137-4","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 ","pages":"Pages S1-S179"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encuesta nacional sobre la imagen nuclear en patología ósea infecciosa: resultados y recomendaciones diagnósticas del Grupo de Trabajo de Patología Musculoesquelética (GT-PME)","authors":"E. Noriega-Álvarez ,&nbsp;A. Moreno-Ballesteros ,&nbsp;M. Velasco Nuño ,&nbsp;J.M. Cordero García ,&nbsp;J.J. Rosales Castillo ,&nbsp;U.V. Schmülling ,&nbsp;E. López Rodríguez ,&nbsp;A. Rigabert Sánchez-Junco ,&nbsp;B. Rodríguez Alfonso","doi":"10.1016/j.remn.2025.500165","DOIUrl":"10.1016/j.remn.2025.500165","url":null,"abstract":"<div><div>The continued increase in demand for diagnosis and monitoring of infectious bone diseases, along with the introduction of new equipment, radiopharmaceuticals, and techniques for this purpose, has made it necessary to dynamically update the existing protocols and recommendations. Therefore, the MSP-WG conducted a survey for spanish hospitals to complete and develop recommendations in the form of algorithms, in an attempt to combine existing scientific evidence with the reality of national clinical practice.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500165"},"PeriodicalIF":1.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influencia de la fiebre en el 18F-FDG PET/TC in vivo utilizando un parámetro cuantitativo SUL","authors":"S. Huang ,&nbsp;M.S. Fang ,&nbsp;M. Zhao ,&nbsp;F. Li","doi":"10.1016/j.remn.2025.500127","DOIUrl":"10.1016/j.remn.2025.500127","url":null,"abstract":"<div><h3>Introduction</h3><div>Fever can affect the identification and efficacy evaluation of tumors on the ¹⁸F-FDG PET/CT, and this effect can be reduced by referring to normal tissue metabolism.The aim of the study was to analyze the influence of fever on glucose metabolism in the mediastinal blood pool, liver, spleen, and bone marrow utilizing PET/CT quantitative parameter SUV normalized by lean body mass(SUL).</div></div><div><h3>Materials and methods</h3><div>30 patients with fever of unknown origin and 24<!--> <!-->patients for tumor screening with normal body temperature within 3<!--> <!-->weeks, who underwent ¹⁸F-FDG PET/CT in our department, were analysed retrospectively. The SUL_max and SUL_mean of the mediastinal blood pool, liver, spleen, and bone marrow were respectively measured in the two groups, and the differences between the two groups were compared by independent sample t test or Wilcoxon-Mann-Whitney test.</div></div><div><h3>Results</h3><div>The SUL_max and SUL_mean of the liver in the fever group were lower than those in the control group (<em>P</em> <!-->=<!--> <!-->.001, .013). The SUL_max and SUL_mean of spleen and bone marrow in the fever group were higher than in the control group (all <em>P</em> <!-->&lt;<!--> <!-->.05). The SUL_max of the mediastinal blood pool in the fever group was lower than that in the control group (<em>P</em> <!-->=<!--> <!-->.007), but there was no significant difference in SUL_mean of the mediastinal between the fever group and the control group (T<!--> <!-->=<!--> <!-->1.181, <em>P</em> <!-->=<!--> <!-->.221).</div></div><div><h3>Conclusion</h3><div>The fever can affect the glucose metabolism in internal organs. But there was no significant difference in the SUL_mean of mediastinal blood pool. Perhaps the SUL_mean of the blood pool can be invoked as a calibration parameter in the evaluation of efficacy in tumor patients with fever.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500127"},"PeriodicalIF":1.6,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolucionando el tratamiento del cáncer de próstata: la terapia dirigida al antígeno prostático específico en el enfoque moderno terapéutico","authors":"A. Ricaurte Fajardo ,&nbsp;V. Marulanda Corzo ,&nbsp;S. Ruder ,&nbsp;D.R. Cardoza-Ochoa ,&nbsp;C.E. Granados ,&nbsp;D. Yadav ,&nbsp;D. Lopez ,&nbsp;M. Fatima ,&nbsp;S. Dutruel ,&nbsp;E. O’Dwyer ,&nbsp;J.R. Osborne ,&nbsp;S.T. Tagawa ,&nbsp;S. Huicochea Castellanos","doi":"10.1016/j.remn.2025.500162","DOIUrl":"10.1016/j.remn.2025.500162","url":null,"abstract":"<div><div>Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has reshaped the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), offering new therapeutic possibilities beyond conventional approaches. Among the most promising strategies is lutetium-177 PSMA-617, which has shown significant benefits in overall survival and durable PSA responses, as demonstrated in several clinical trials.</div><div>At the same time, the development of novel radionuclides such as actinium-225 has opened the door to more potent treatments capable of overcoming prior resistance, particularly in patients previously exposed to beta emitters. The use of PSMA PET imaging and the identification of predictive biomarkers have helped refine patient selection, contributing to a more personalized approach. Comparative studies with agents like cabazitaxel have further supported the safety and effectiveness of this strategy.</div><div>This article provides a critical overview of clinical advances in PSMA-targeted radionuclide therapy, examines emerging combination treatments, reviews the development of alpha-emitting agents, and highlights the role of personalized dosimetry in clinical practice, underlining the growing importance of this therapeutic modality across different stages of prostate cancer.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500162"},"PeriodicalIF":1.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/TC en la sospecha de linfoma primario del SNC: evaluación del compromiso sistémico y guía para biopsia","authors":"P. Dauden-Onate ,&nbsp;C. Gamila Wakfie-Corieh ,&nbsp;R.M. Couto-Caro ,&nbsp;M.L. Suarez-Solis ,&nbsp;C. Benavente-Cuesta ,&nbsp;M.N. Cabrera-Martín","doi":"10.1016/j.remn.2025.500140","DOIUrl":"10.1016/j.remn.2025.500140","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500140"},"PeriodicalIF":1.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: «Evaluación del papel de la sarcopenia y los parámetros [18F]FDG PET/TC en el pronóstico del adenocarcinoma ductal pancreático»","authors":"D. Mut Surmeli","doi":"10.1016/j.remn.2025.500125","DOIUrl":"10.1016/j.remn.2025.500125","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500125"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detección incidental de carcinoma tiroideo y adenoma paratiroideo con 18F-Fluorocolina PET/CT","authors":"G. Cuesta Domingo ,&nbsp;C. Rodríguez Rey ,&nbsp;A. Ortega Candil ,&nbsp;P. Nespral Torres ,&nbsp;S. Ochagavía Cámara ,&nbsp;M.N. Cabrera Martín","doi":"10.1016/j.remn.2025.500136","DOIUrl":"10.1016/j.remn.2025.500136","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500136"},"PeriodicalIF":1.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factores natriuréticos y biomarcadores de inflamación como predictores de supervivencia en la terapia con [177Lu]Lu-DOTA-TATE de los tumores neuroendocrinos","authors":"A. Piñeiro Donis ,&nbsp;L. Menéndez-Muros ,&nbsp;J.L. Villa-Palacios ,&nbsp;E. Triviño-Ibáñez ,&nbsp;M.A. Muros-Fuentes","doi":"10.1016/j.remn.2025.500138","DOIUrl":"10.1016/j.remn.2025.500138","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the prognostic value of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and other biomarkers of inflammation in patients with neuroendocrine tumors (NETs) treated with [¹⁷⁷Lu]Lu-DOTA-TATE (Lutathera®). The prognostic value of histological characteristics of the tumor was also analyzed.</div></div><div><h3>Patients and methods</h3><div>Prospective study of a cohort of patients with advanced and metastatic NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Before the administration of doses, NT-proBNP, hemoglobin, hematocrit, C-reactive protein, leukocytes, lymphocytes, neutrophils, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been determined. Overall survival (OS) and progression free survival (PFS) were calculated, using the Kaplan-Meier method, and curves were compared with a log-rank test. To determine the predictor variables of OS, a Cox regression model was fitted.</div></div><div><h3>Results</h3><div>48 NET patients treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Median OS was 96<!--> <!-->months and PFS was 29<!--> <!-->months. Factors associated with lower OS were: NTproBNP values<!--> <!-->&gt;<!--> <!-->300<!--> <!-->pg/mL (HR: 10.5; <em>P</em> <!-->=<!--> <!-->.005) in the subgroup of patients with grades<!--> <!-->2-3, in addition to inflammatory indices NLR<!--> <!-->&gt;<!--> <!-->2 (HR: 3.87; <em>P</em> <!-->=<!--> <!-->.049) and PLR<!--> <!-->&gt;<!--> <!-->300 (HR: 11.88; <em>P</em> <!-->=<!--> <!-->.01) and higher tumor grade (HR: 6.45; <em>P</em> <!-->=<!--> <!-->.011). PLR<!--> <!-->&gt;<!--> <!-->300 (HR: 5.506; <em>P</em> <!-->=<!--> <!-->.003) was also associated with lower PFS. In contrast, higher levels of lymphocytes (HR: 0.21; <em>P</em> <!-->=<!--> <!-->.002), hemoglobin (HR: 0.65; <em>P</em> <!-->=<!--> <!-->.041) and hematocrit (HR: 0.862; <em>P</em> <!-->=<!--> <!-->.031) were associated with higher OS, without significant changes in PFS.</div></div><div><h3>Conclusion</h3><div>In patients with NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE, the determination of natriuretic factors (NT-ProBNP) and other inflammatory biomarkers may be useful as predictors of survival and prognostic factors.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500138"},"PeriodicalIF":1.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II","authors":"L. Sancho ,&nbsp;A. Roteta ,&nbsp;I. Torres ,&nbsp;M. de Arcocha ,&nbsp;R. Ramos ,&nbsp;M.L. Domínguez ,&nbsp;J.J. Rosales ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;en nombre del Grupo de Oncología de la SEMNim","doi":"10.1016/j.remn.2025.500128","DOIUrl":"10.1016/j.remn.2025.500128","url":null,"abstract":"<div><div>The state of the art and future perspectives of new radionuclides in Nuclear Medicine continue to evolve, driven by the development of isotopes with innovative applications in theragnostics.</div><div>In this second part of the continuing education series, the clinical and therapeutic applications of terbium, actinium, and bismuth are analyzed in depth. The use of the 4<!--> <!-->terbium isotopes (terbium-149, terbium-152, terbium-155, and terbium-161) is described, offering a versatile system for both diagnosis and treatment due to their chemical similarity to lutetium-177, along with the challenges related to their production and availability. Additionally, actinium-225, a powerful alpha-emitting radionuclide, is reviewed for its growing role in targeted alpha therapy, particularly in prostate cancer and neuroendocrine tumors. Finally, bismuth-213, derived from actinium-225, is analyzed for its short half-life, making it a viable option for localized and selective therapies.</div><div>Despite technical and production challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities in Nuclear Medicine.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500128"},"PeriodicalIF":1.6,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modelo para predecir riesgo de fallecimiento de causa cardíaca según características clínicas y parámetros del gated-SPECT de perfusión miocárdica","authors":"G. Rodríguez Cabalé ,&nbsp;E. Rodríguez Cabalé ,&nbsp;V. Pubul Núñez ,&nbsp;Á. Ruibal Morell","doi":"10.1016/j.remn.2025.500132","DOIUrl":"10.1016/j.remn.2025.500132","url":null,"abstract":"<div><h3>Background</h3><div>Coronary artery disease is a complex, multifactorial process with high prevalence and morbidity-mortality. Single photon emission computed tomography (SPECT) myocardial perfusion imaging synchronized with the electrocardiogram (gated-SPECT) is a non-invasive imaging technique that has demonstrated high sensitivity and specificity for diagnosis and staging. To better predict the risk of adverse events, it is necessary to analyze the simultaneous behavior of clinical elements and diagnostic tests, a type of study that is scarce in the current literature. This research evaluated the relationship between clinical characteristics and gated-SPECT myocardial perfusion parameters with progression to cardiac death; subsequently, a model was built to predict the risk of such an outcome.</div></div><div><h3>Methods</h3><div>An observational, longitudinal, and retrospective study was conducted with 2 230 patients who underwent this test due to suspected coronary artery disease. Clinical characteristics, test parameters, and progression to cardiac death were collected and the relationships between them were studied. A logistic regression model was built to study the relationships between the variables and their influence on the probability of progression to cardiac death.</div></div><div><h3>Results</h3><div>Clinical characteristics associated with a higher probability of cardiac death were male sex (OR<!--> <!-->=<!--> <!-->5.104, <em>P</em> <!-->=<!--> <!-->0.004), peripheral arterial disease (OR<!--> <!-->=<!--> <!-->7.175, <em>P</em> <!-->&lt;<!--> <!-->0.001), and diabetes mellitus (OR<!--> <!-->=<!--> <!-->3.159, <em>P</em> <!-->=<!--> <!-->0.013). The gated-SPECT parameters associated with a higher risk of this outcome were VTS ≥70<!--> <!-->ml (OR<!--> <!-->=<!--> <!-->12.257, <em>P</em> <!-->&lt;<!--> <!-->0.001), EF &lt;<!--> <!-->50% (OR<!--> <!-->=<!--> <!-->10.757, <em>P</em> <!-->&lt;<!--> <!-->0.001), VTD ≥140<!--> <!-->ml (OR<!--> <!-->=<!--> <!-->8.884, <em>P</em> <!-->&lt;<!--> <!-->0.001), ventricular dilation (OR<!--> <!-->=<!--> <!-->8.959, <em>P</em> <!-->&lt;<!--> <!-->0.001), and reversible defects (OR<!--> <!-->=<!--> <!-->7.454, <em>P</em> <!-->=<!--> <!-->0.001). Fixed defects, parietal motility abnormalities, the presence of both reversible and fixed defects, and the hyperdynamic gated state were also associated with a higher risk of cardiac death but with lower ORs.</div><div>The logistic regression model showed good overall performance and high ability to determine progression to cardiac death, close to perfect predictive capacity (AUC<!--> <!-->=<!--> <!-->0.9656).</div></div><div><h3>Conclusions</h3><div>It is necessary to employ total cardiovascular risk models that include results from diagnostic tests such as gated-SPECT. The constructed model demonstrated good overall performance and is a valid proposal for predicting the risk of death due to cardiac causes.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500132"},"PeriodicalIF":1.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}